Please assess the completion status of the following clinical trial:

Trial Title: Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 to 49 years, inclusive.~2. Responsive to inhaled endotoxin; defined as a reduction of 10% or greater in forced expiratory volume in 1 second (FEV1) following inhalation of 20 µg equivalent of Clinical Center Reference Endotoxin.~3. Have a body weight greater than 65 kg and a body mass index (BMI) below 30.~4. Have normal lung function, defined as:~   * Forced vital capacity (FVC) \> 80% of that predicted value;~  * FEV1 \> 80% of that predicted value; and~  * FEV1/FVC ratio \> 80% of predicted values.~5. Have vital signs within the normal range, as follows:~   * Oral body temperature: 35.0 to 36.5 °C.~  * Blood pressure (BP):~  * After at least 3 minutes of rest, measured in the supine position:~  * Systolic BP: 90 to 140 mm Hg.~  * Diastolic BP: 50 to 90 mm Hg.~  * Then, after 1 minute standing:~  * Systolic BP: no more than a 20 mmHg decrease.~  * Diastolic BP: no more than a 10 mm Hg decrease.~  * Heart rate: after at least 3 minutes of rest and measured in the supine position: 40 to 90 beats per minute (bpm).~6. Have a hemoglobin level of 12.0 g/dL or more.~7. Have been a non-smoker for the preceding 12 months.~8. Willing and able to give written informed consent and to comply with the requirements of the study.~9. Female subjects must not be pregnant or lactating.~10. All subjects who are sexually active must use a medically acceptable and highly effective method of birth control for the duration of the study, and continue for 90 days after the end of treatment.~    -~Exclusion Criteria:~1. Have any condition, including findings in the medical history or in the pre-study assessments, which, in the opinion of the investigator, constitute a risk or contraindication for the participation of the subject to the study, or that could interfere with the study objectives, conduct, or evaluation including, but not limited to:~   * Any clinically significant abnormality in the results of pre-study safety laboratory tests.~  * A positive test for drugs of abuse or alcohol breath test.~  * Positive results from serum tests for Hepatitis B surface antigen (not due to vaccination), Hepatitis C, or Human Immunodeficiency Virus.~  * History or presence of lung disease including asthma, chronic obstructive lung disease, or emphysema.~  * History of atopy, including hay fever or atopic dermatitis.~  * History or presence of liver disease.~  * Hyperthyroidism, hypoglycemia, hyperglycemia, or diabetes mellitus.~  * History or presence of autoimmune disorders including myositis, hepatitis, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, Sjögren's syndrome, thyroiditis, or systemic lupus erythaematosus.~  * Occurrence of any acute infection within the last 2 weeks before dosing.~2. Presence or history of any severe allergic reactions; or history of allergy to any medications that may be used or prescribed in the course of this study (eg, albuterol, prednisolone, acetaminophen, aspirin or other non-steroidal anti-inflammatory agents, or adalimumab).~3. History or presence of drug or alcohol abuse. (i;e. average daily intake of 3 units or a maximum weekly intake of greater than 21 units (1 unit equals 340 milliliters \[ml\] of beer, 115 ml of wine, or 43 ml of spirits).~4. History or active manifestation of a serious psychiatric illness including depression, suicidal ideation, or psychosis.~5. Positive test for latent tuberculosis.~6. Loss or donation of blood within 12 weeks prior to entry into the study, or plasma donation within 1 week prior to entry into the study.~7. Use of any prescription drugs within 2 weeks or over-the-counter medication, including herbal supplements or multivitamins, within 1 week before drug administration without prior approval from the investigator.~8. Use of any medication that may impact the results of any of the challenges, interfere with any other medications potentially used in the study, including steroids, beta blockers, or non-steroidal anti-inflammatory agents.~9. Previous participation in this study, or administration of any investigational drug within 12 weeks prior to entry into the study.~10. Exposure to endotoxin, within 12 weeks of signing the informed consent for this study.~11. History of exposure to keyhole limpet hemocyanin (KLH), dog rabies vaccine, or history of immunization with inactivated Hepatitis A virus.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- adalimumab (Type: ACTIVE_COMPARATOR): adalimumab 40 mg by subcutaneous way 7 days before endotoxin inhalation
- methylprednisolone (Type: ACTIVE_COMPARATOR): methylprednisolone 20 mg daily , 7 days before endotoxin inhalation
- control (Type: NO_INTERVENTION): no intervention, 7 days before endotoxin inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete